Medication Reconciliation During Pregnancy Transitions: A Comprehensive Clinical Review

Abstract

Medication reconciliation during pregnancy transitions is a critical process aimed at optimizing pharmacotherapy and minimizing medication errors as pregnant patients move across different levels of care. With physiological changes influencing pharmacokinetics and pharmacodynamics, accurate medication management is paramount to prevent adverse maternal and fetal outcomes. This review synthesizes current evidence, guidelines, and practical strategies for effective medication reconciliation during antenatal, intrapartum, and postpartum transitions, providing actionable insights for clinicians involved in maternal healthcare.

Introduction

Pregnant individuals frequently undergo care transitions between outpatient, inpatient, and specialist settings. Each transition presents a vulnerable window for medication discrepancies that may result in adverse drug events, teratogenic exposures, or suboptimal therapy. Medication reconciliation the systematic process of creating the most accurate list of a patient's current medicines and comparing it to the physician's orders at every transition has emerged as a best practice endorsed by major healthcare organizations. This article critically examines the epidemiology, pathophysiology, risk factors, clinical features, diagnosis, management, emerging therapies, and guideline recommendations related to medication reconciliation in pregnancy transitions.

Epidemiology / Disease Burden

Medication errors are a leading cause of preventable harm in pregnant patients, with studies reporting up to 67% of women being prescribed at least one medication during pregnancy. Transitions of care, such as hospital admission for delivery or inter-facility transfer, are high-risk periods for discrepancies. The World Health Organization and Joint Commission have identified medication reconciliation as a key strategy to reduce perinatal medication errors, which are estimated to affect 5-10% of hospitalized pregnant women globally. Chronic comorbidities, polypharmacy, and fragmented care exacerbate this burden, making robust reconciliation processes essential.

Pathophysiology

The physiological changes of pregnancy including increased plasma volume, altered renal clearance, and hepatic enzyme modulation can impact drug absorption, distribution, metabolism, and elimination. Hormonal fluctuations may modify drug-receptor interactions and placental transfer, while comorbidities such as hypertension or diabetes can further complicate pharmacotherapy. These changes demand continuous review and adjustment of medication regimens at every care transition to maintain therapeutic efficacy and minimize fetotoxicity or maternal harm.

Risk Factors

Several factors heighten the risk of medication discrepancies during pregnancy transitions. High-risk groups include patients with multiple comorbidities, those on complex regimens (e.g., antiepileptics, anticoagulants), limited health literacy, language barriers, and lack of coordinated communication among providers. Additional risks stem from unintentional duplications, omissions, or inappropriate substitutions that may occur when medication histories are incomplete or inaccurate.

Clinical Features

Medication-related adverse events in pregnant patients can manifest as maternal complications (e.g., hypertensive crisis, hypoglycemia, hemorrhage), fetal toxicity (e.g., congenital malformations, growth restriction), or suboptimal disease control. Clinical suspicion should be high in patients presenting with unexplained symptoms following a transition of care, particularly where medication changes are recent or poorly documented. Early recognition and prompt intervention are vital to mitigate harm.

Diagnosis

Diagnosis of medication discrepancies relies on thorough reconciliation processes, including patient interviews, review of prescription records, pharmacy databases, and collaboration with multidisciplinary teams. Electronic health records (EHRs) with integrated medication reconciliation modules have improved the detection of discrepancies but require accurate data entry and provider engagement. Standardized tools and checklists, such as the Medication Discrepancy Tool (MDT), can further aid systematic identification of errors at each transition.

Treatment & Management

Effective medication reconciliation involves five key steps: (1) compiling a comprehensive list of current medications, (2) comparing against new medication orders, (3) identifying and resolving discrepancies, (4) documenting reconciled lists, and (5) communicating updates across care teams. Engaging clinical pharmacists, leveraging EHR capabilities, and incorporating patient education are integral components. Patient-centered discussions about risks and benefits, especially when adjusting medications with known teratogenicity or withdrawal risks, should be prioritized. Ongoing monitoring and follow-up are essential to ensure sustained medication safety.

Recent Advances / Emerging Therapies

Recent advances in medication reconciliation include EHR-based clinical decision support systems, mobile health applications for self-reporting, and artificial intelligence tools for predictive risk assessment. Pharmacogenomics and therapeutic drug monitoring are increasingly utilized to personalize dosing and monitor for adverse effects in pregnancy. Telemedicine platforms have also facilitated multidisciplinary collaboration, especially in rural or resource-limited settings. Emerging research focuses on integrating maternal-fetal medicine, pharmacy, and informatics to enhance reconciliation outcomes.

Guideline Recommendations

Multiple guidelines underscore the necessity of medication reconciliation at every pregnancy care transition. The American College of Obstetricians and Gynecologists (ACOG), the Institute for Safe Medication Practices (ISMP), and the World Health Organization recommend standardized protocols, multidisciplinary engagement, and patient involvement. Specific recommendations include reconciling medications at the first prenatal visit, upon hospital admission and discharge, and in the postpartum period. Documentation of all medication changes and clear communication with primary care providers are emphasized to promote continuity and safety.

Conclusion

Medication reconciliation during pregnancy transitions is a cornerstone of safe perinatal care, addressing the unique pharmacological and clinical challenges encountered in this population. Ongoing vigilance, multidisciplinary collaboration, and adoption of technological innovations are key to minimizing errors and optimizing maternal-fetal outcomes. Adherence to evidence-based guidelines, coupled with patient-centered approaches, can substantially reduce the burden of medication-related harm during these critical transitions.